<SEC-DOCUMENT>0001104659-20-025388.txt : 20200226
<SEC-HEADER>0001104659-20-025388.hdr.sgml : 20200226
<ACCEPTANCE-DATETIME>20200226161530
ACCESSION NUMBER:		0001104659-20-025388
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200226
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200226
DATE AS OF CHANGE:		20200226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		20655855

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2011055d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="text-align: center; font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Date of Report (Date of earliest event
reported): February 26, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of incorporation)</B></P></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>200 Connell Drive, Suite 1500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Berkeley Heights, NJ 07922</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive offices
and zip code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Securities
registered pursuant to Section&nbsp;12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 40%"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 20%"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 40%"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CYCC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Preferred Stock, $0.001 par value</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CYCCP</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Emerging
growth company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 2.02</B></TD><TD STYLE="text-align: justify"><B>Results of Operations and Financial Condition.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The information set forth under this &ldquo;Item
2.02. Results of Operations and Financial Condition,&rdquo; including the exhibit attached hereto, shall not be deemed &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference
into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Attached as Exhibit 99.1 is a copy of a
press release of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;), dated February 26, 2020, announcing certain
financial results for the fourth quarter and full year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The Company will conduct a conference call
to review its financial results on February 26, 2020, at 4:30 p.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.9in"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt"><A HREF="tm2011055d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding-top: 3pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt"><A HREF="tm2011055d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press release announcing financial results for the fourth quarter and full year ended December 31, 2019, dated February 26, 2020.</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="white-space: nowrap; width: 32%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Name:</FONT>&nbsp;&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance, </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: February 26, 2020</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2011055d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><IMG SRC="image_002.jpg" ALT=""></TD>
    <TD STYLE="text-align: right; width: 50%; vertical-align: middle"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Cyclacel Pharmaceuticals, Inc.</P>


</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="margin: 0; text-align: right"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: rgb(163,163,163) 1.5pt solid; text-align: center; padding-bottom: 3pt; width: 100%"><IMG SRC="image_001.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&ndash; Anticancer Activity of Fadraciclib
(CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>and Fadraciclib-venetoclax Combination
in Patients with Relapsed or Refractory AML/MDS and CLL &ndash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&ndash;
Conference Call Scheduled February 26, 2020 at 4:30 p.m. EDT &ndash;</I></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B>Berkeley Heights, NJ, February 26,
2020</B> - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;), a biopharmaceutical
company developing innovative medicines based on cancer cell biology, today reported its financial results and business highlights
for the fourth quarter and full year ended December 31, 2019. The Company's net loss applicable to common shareholders for the
three months and year ended December 31, 2019 was $2.4 million and $8.0 million, respectively. As of December 31, 2019, cash and
cash equivalents totaled $11.9 million. Based on current spending, cash on hand provides the Company with sufficient resources
to fund all planned operations including research and development through Q1 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&ldquo;Our fadraciclib (CYC065) CDK inhibitor is establishing
a leadership position among MCL1 suppressing compounds in clinical development,&rdquo; said Spiro Rombotis, President and Chief
Executive Officer. &ldquo;After enrolling approximately 60 patients to date with multiple dosing schedules in three Phase 1 dose
escalation studies in patients with relapsed or refractory (R/R) solid tumors and hematological malignancies, we have demonstrated
safety, proof of mechanism by durable suppression of MCL1 and anticancer activity of fadraciclib as single agent and in combinations.
Encouragingly, a heavily pretreated patient with MCL1 amplified endometrial cancer has received over 10 cycles of fadraciclib monotherapy
achieved a confirmed partial response (PR) and a further reduction in her target tumor lesions of 73%. Based on data thus far,
we are developing a precision medicine strategy to further evaluate fadraciclib as monotherapy and in combinations. In our Phase
1 trial of a combination of fadraciclib and venetoclax in patients with relapsed or refractory AML/MDS, we have enrolled 11 patients
and reached dose level five and in CLL 3 patients and dose level two. Our clinical stage pipeline, comprising of fadraciclib, sapacitabine
and CYC140, our PLK1 inhibitor, is a central element of our strategy of building an innovative pipeline addressing cancer resistance
and DNA damage response.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Corporate Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC065-01
Phase 1 part 2 single agent i.v. </B>&ndash; In November 2019, we reported anticancer activity in a heavily pretreated a patient
with MCL1 amplified endometrial cancer who achieved a radiographically confirmed partial response (PR) after 4 cycles at 213mg.
The patient remains on study after 10 cycles and shrinkage of her target tumor lesions has reached 73%. An additional patient
with cyclin E amplified ovarian cancer achieved stable disease after 4 cycles at 213mg with 29% tumor shrinkage. We are expanding
the 213mg dose level to recruit additional patients and determine the recommended Phase 2 dose.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC065-01
Phase 1 part 3 single agent p.o. </B>&ndash; We are evaluating an oral capsule form of fadraciclib in patients with advanced solid
tumors and have enrolled two patients at 75mg and 150mg once daily. Pharmacokinetic (PK) data in the two patients demonstrated
a predictable PK profile closely overlapping the i.v. form with encouraging exposure levels.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Wingdings">&thorn;</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922, USA Tel +1
908 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;1 James Lindsay
Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: blue"><U>www.cyclacel.com</U></FONT>
 &ndash; <FONT STYLE="color: blue"><U>info@cyclacel.com</U></FONT></P>



</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC065-03
Phase 1 fadraciclib i.v. and venetoclax p.o.</B> &ndash; We have dosed 11 heavily pretreated patients with R/R AML in five dose
levels up to 200 mg/m<SUP>2</SUP> in combination with the BCL2 inhibitor venetoclax. Evidence of anticancer activity has been
observed in multiple patients with blast reductions in peripheral blood. Preclinical AML data demonstrated synergy of fadraciclib
and venetoclax, suggesting that targeting both BCL2 and MCL1 may be more beneficial than inhibiting either protein alone.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC065-02
Phase 1 fadraciclib i.v. and venetoclax p.o.</B> &ndash; We have dosed 3 patients with R/R CLL in two dose levels up to 85 mg/m<SUP>2
</SUP>in combination with venetoclax. Evidence of anticancer activity has been observed in two patients who experienced reduction
in lymph node size with one of them achieving MRD negative status. Preclinical CLL data demonstrated synergy of fadraciclib and
venetoclax, suggesting that targeting both BCL2 and MCL1 may be more beneficial than inhibiting either protein alone.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC682-11
Phase 1b/2 part 2 sapacitabine p.o. and venetoclax p.o.</B>&ndash; We have enrolled 10 patients in two dose cohorts in our DNA
Damage Response (DDR) program evaluating an oral combination of sapacitabine and venetoclax in patients with R/R AML/MDS. Sapacitabine
is a nucleoside analogue that is active in AML and MDS R/R to prior therapy such as cytarabine or hypomethylating agents. Preclinical
data demonstrated synergy of sapacitabine with BCL2 inhibition which may offer an effective, oral treatment regimen for patients
who have failed front-line therapy.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC140-01
Phase 1 CYC140 i.v. </B>- We have enrolled 4 patients in our first-in-human, dose escalation study evaluating CYC140 in patients
with advanced leukemias. CYC140 is a small molecule, selective polo-like-kinase 1 (PLK1) inhibitor that has demonstrated potent
and selective target inhibition and high activity in xenograft models of human cancers.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">More information
on our clinical trials can be found at <FONT STYLE="color: Blue"><U>www.clinicaltrials.gov</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>Key Business Objectives for 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Report
updated Phase 1 safety, PK and efficacy data for fadraciclib utilizing a frequent i.v. dosing schedule in patients with advanced
solid cancers;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Report
initial safety and PK data from the Phase 1 study of an oral formulation of fadraciclib;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Report
initial safety and proof of concept data from the fadraciclib-venetoclax Phase 1 studies in R/R AML/MDS and CLL;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Report
initial data from the sapacitabine-venetoclax Phase 1b/2 study in patients with R/R AML/MDS;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Report
initial data from the CYC140 Phase 1 first-in-human study in R/R leukemias; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Report
data from the Phase 1b/2 IST of sapacitabine-olaparib combination in patients with BRCA mutant metastatic breast cancer when reported
by the investigators.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>Financial Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">As of December 31, 2019, cash and cash
equivalents totaled $11.9 million, compared to $17.5 million as of December 31, 2018. The decrease of $5.6 million was primarily
due to net cash used in operating activities of $9.4 million, offset by $3.8 million of net cash provided by financing activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">Revenues for the three months and year
ended December 31, 2019 amounted to $0 compared to $0.2 million for the same periods in 2018. The 2018 revenue related to a collaboration,
licensing and supply agreement with ManRos Therapeutics, entered into in June&nbsp;2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">Research and development expenses were
$1.4 million and $4.7 million for the three months and year ended December 31, 2019 as compared to $1.1 million and $4.3 million
for the same periods in 2018. Research and development expenses relating to the transcriptional regulation, CDK inhibitor program
with fadraciclib increased by $0.5 million from $2.5 million for the year ended December 31, 2018 to $3.0 million for the year
ended December 31, 2019, as the clinical evaluation of fadraciclib progressed. Research and development expenses relating to the
DDR, sapacitabine program decreased by $0.4 million from $0.9 million for the year ended December 31, 2018 to $0.5 million for
the year ended December 31, 2019, primarily as a result of expenditure related to clinical trial drug supply manufacturing in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">General and administrative expenses
for the three months and year ended December 31, 2019 were $1.4 million and $5.0 million respectively, compared to $1.5 million
and $5.4 million for the same periods of the previous year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">Total other income, net for the three
months and year ended December 31, 2019 were $0.1 million and $0.6 million, compared to $0.1 million and $0.9 million for the same
periods of the previous year. The decrease of $0.3 million for the year ended December 31, 2019 is primarily related to a reduction
in income received under an Asset Purchase Agreement with ThermoFisher Scientific.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">United Kingdom research &amp; development
tax credits were $0.4 million and $1.3 million for the three months and year ended December 31, 2019 as compared to $0.4 million
and $1.3 million for the same periods in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">Net loss for the three months and year
ended December 31, 2019 were $2.3 million and $7.8 million compared to $2.0 million and $7.3 million for the same periods in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">The Company raised net proceeds of
approximately $4.1 million during 2019, from its <FONT STYLE="color: #2e2e2e">Common Stock Sales Agreement with H.C. Wainwright</FONT>,
which is now completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">The Company <FONT STYLE="color: #231f20">estimates
that cash resources </FONT>of $11.9 million as of December 31, 2019 <FONT STYLE="color: #231f20">will fund currently planned programs
through the first quarter of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B>Conference call information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">US/Canada call: (877) 493-9121 / international call: (973) 582-2750&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">US/Canada archive: (800) 585-8367 / international archive: (404)
537-3406&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Code for live and archived conference call is 6761906.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">For the live and archived webcast,
please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90
days and the audio replay for 7 days.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Cyclacel Pharmaceuticals
is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation
and DNA damage response biology. The transcriptional regulation program is evaluating fadraciclib as a single agent in solid tumors
and in combination with venetoclax in patients with relapsed or refractory AML/MDS and CLL. The DNA damage response program is
evaluating an oral combination of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS. An IST is evaluating
an oral combination of sapacitabine and olaparib in patients with BRCA mutant breast cancer. The anti-mitotic program is evaluating
CYC140, a PLK1 inhibitor, in advanced leukemias/MDS patients. Cyclacel's strategy is to build a diversified biopharmaceutical
business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit
<FONT STYLE="color: #0000ed"><U>www.cyclacel.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">This
news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results
to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.
Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization
of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future
research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially
include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety
and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval
to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the
risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product
candidates. You are urged to consider statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot;
 &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot;
 &quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot;
 &quot;designed,&quot; &quot;goal,&quot; or the negative of those words or other comparable words to be uncertain and forward-looking.
For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report
on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at <FONT STYLE="color: blue"><U>www.sec.gov</U></FONT>.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>Contacts</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1.25in"><FONT STYLE="color: #2e2e2e">Company: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: #2e2e2e">Paul McBarron, (908) 517-7330,&nbsp;</FONT><FONT STYLE="color: Blue"><U>pmcbarron@cyclacel.com</U></FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1.25in"><FONT STYLE="color: #2e2e2e">Investor Relations:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: #2e2e2e">Russo Partners LLC, </FONT>Jan Medina, (646) 942-5632, <FONT STYLE="color: Blue"><U>Jan.Medina@russopartnersllc.com</U></FONT>&#9;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&copy; Copyright
2020 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(In $000s, except
share and per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Revenues:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total revenues</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">150</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,142</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,430</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,474</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,363</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,616</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,793</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,466</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,793</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Foreign exchange gains (losses)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(48</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(14</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Interest income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">93</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">47</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Other income, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">50</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Total other income (expense), net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">95</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">41</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Loss before taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,371</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,752</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax benefit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">353</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">449</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,018</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,303</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Dividend on convertible exchangeable preferred shares</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(51</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss applicable to common shareholders</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,068</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,354</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Basic and diluted earnings per common share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss per share &ndash; basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.17</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Weighted average common shares outstanding</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: right">12,381,031</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: right">17,199,974</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSOLIDATED BALANCE SHEET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(In $000s, except share, per share, and
liquidation preference amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2018</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 72%; font-size: 10pt; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">17,504</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">11,885</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">2,283</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">2,132</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left">Total current assets</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">19,787</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">14,017</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Property and equipment, net</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">36</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">27</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Right-of-use lease asset</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">1,264</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: right">19,823</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: right">15,308</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,719</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">890</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Accrued and other current liabilities</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">1,732</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">1,530</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left">Total current liabilities</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">4,451</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">2,420</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0in; font-size: 10pt; text-align: left">Lease liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">1,191</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other liabilities</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">4,551</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">3,611</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">15,272</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">11,697</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">19,823</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">15,308</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">SOURCE: Cyclacel Pharmaceuticals,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ ^@#Z  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  6 9 # 2(  A$! Q$!_\0
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MWR?,S2!716QZY^TOG_A0/QDV_>_X0'Q!M&<9;[--CG(P <98$%<Y!!Q7R?\
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-B1!&C[EBC"%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ ^@#Z  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !, ,@# 2(  A$! Q$!_\0
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MV2:2:5I**2BG'W6E;1I.+2<?=E;FC>,HME%%%,84444 %%%% !1110 4444
M%%%% !1110 4444 ?-_[3?QZ\/\ [-WP*\??&GQ);MJ=OX0T5Y])T&*5+";Q
M3XFORMEX8\,V]Q*TGD-K6LW-I92W/ESFRLY+J^%K<M;"%_YW_P!A+]F*V_:&
M\1_$G_@H/^VIJNG7OPOT;7-8\9O_ ,),DD7AWQ[XAT6*:XUS7=2AF5HQ\,?
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M7W$>99DZS6M3^P:U+@^3NE*:C5Q&1T<#*I*5.C6_>+EIJGR? _PP\,W7Q/\
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MMTWQG\*_$YU[0-3T1)->T"+PW8R3OI,NH1:QI;Q7,<D&IV%K(9#$&C/[044
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M9?M5_ ZU:!- ^/GP\\-SZS\=_!FG6JJEO8_&_P"&E@K:IX_6WM2J3?$SX?\
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I5_%>[UNV%%%%4 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
